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Aims: Non-invasively assessed skin autofluorescence (SAF) measures advanced glycation endproducts (AGEs) in
the dermis. SAF correlates with dermal AGEs in Caucasians and Asians, but studies in dark-skinned subjects are
lacking. In this pilot we aimed to assess whether SAF signal is representative of intrinsic fluorescence (IF) and AGE
accumulation in dark skin.
Methods: Skin biopsies were obtained in 12 dark-skinned subjects (6 healthy subjects, median age 22 years; 6
diabetes mellitus (DM) subjects, 65 years). SAF was measured with the AGE Reader, IF using confocal microscopy,
and AGE distribution with specific antibodies. CML and MG-H1 were quantified with UPLC-MS/MS and pento-
sidine with HPLC and fluorescent detection.
Results: SAF correlated with IF from the dermis (405nm, r ¼ 0.58, p < 0.05), but not with CML (r ¼ 0.54, p ¼
0.07). CML correlated with IF from the dermis (405nm, r ¼ 0.90, p < 0.01). UV reflectance and the coefficient of
variation of SAF were negatively correlated (r ¼ -0.80, p < 0.01). CML and MG-H1 were predominantly present
around blood vessels, in collagen and fibroblasts in the dermis.
Conclusion: This proof of concept study is the first to compare non-invasive SAF with AGE levels measured in skin
biopsies in dark-skinned subjects. SAF did not correlate with individual AGEs from biopsies, but was associated
with IF. However, the intra-individual variance was high, limiting its application in dark-skinned subjects on an
individual basis.1. Introduction
Advanced glycation endproducts (AGEs) accumulate during aging [1]
and are acknowledged for their role in the development of several
chronic diseases [2, 3]. Their formation is heterogeneous, although pri-
marily being induced by hyperglycemia and oxidative stress [1]. AGEs
enhance inflammation by binding to the receptor for AGE (RAGE).
Furthermore, AGEs generate cross-links between proteins and accumu-
late in tissues with slow protein turnover (e.g. collagen) such as skin [4,
5] and vascular tissues [6]. Both pathways are involved in the patho-
genesis of age-related chronic diseases.).
m 24 July 2020; Accepted 26 Oc
vier Ltd. This is an open access arSkin autofluorescence (SAF) is a non-invasive proxy of dermal accu-
mulation of AGEs [4, 5]. Previous studies have shown in Caucasian [4, 5]
and Asian subjects [7] that SAF correlates with several AGEs, including
the major AGEs (NƐ-(carboxymethyl)lysine [CML] and pentosidine).
Several studies have shown increased SAF levels in type 1 diabetes (T1D)
and T2D [3], especially in those with diabetic complications [8, 9], and
in renal failure [2, 10]. In addition, SAF is an independent predictor of
cardiovascular events in several high-risk groups [11] and predictor of
the development of T2D, cardiovascular disease and mortality in the
general population [12].
Studies investigating SAF have mainly focused on Caucasians and
Asians [13], because of the compromised reliability of the measurementtober 2020
ticle under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
I.M. Atzeni et al. Heliyon 6 (2020) e05364in subjects with a dark skin type. A previous study from our research
group [14] showed that SAF was generally lower in subjects with dark
skin compared to lighter skin. This is thought to be due to increased
absorption of excitation and emission light by skin constituents (e.g.,
melanin), and not because of actual lower AGE levels.
Koetsier et al. [15] described an algorithm for the AGE Reader SU, to
correct for skin color based on a reflectance level <12%, in order to
calculate SAF independent from skin color. Using this algorithm, the
corrected SAF values demonstrated similar relations with age as for
subjects with a reflectance>12% [15]. Compromised SAF measurements
occur predominantly when UV reflectance values fall below approxi-
mately 6%, which is usually the case in subjects with high skin
pigmentation (Fitzpatrick class V-VI) [16].
SAF has been validated against levels of biochemically assessed AGEs
in skin biopsies in Caucasians [4, 5, 17]. In addition, SAF correlated with
AGE levels in skin samples of Asian subjects with and without diabetes
[7]. However, it is largely unknown what the exact localization is of
different AGEs and intrinsic fluorescence in biopsies in dark skin.
The aim of our exploratory pilot study was to assess whether the non-
invasively assessed SAF signal in dark-skinned subjects is representative
of invasively assessed intrinsic fluorescence and of AGE accumulation in
skin biopsies. Additionally, we assessed AGE localization differences
between younger healthy and older diabetic dark-skinned subjects. These
two small groups were designed expecting a high contrast in AGE accu-
mulation between the groups, as previously seen in Caucasians and
Asians.
2. Subjects
We performed a cross-sectional pilot study in 12 subjects with dark
skin types (Fitzpatrick IV-VI, increasingly dark). This group consisted of 6
older diabetes mellitus (DM), type 1 and 2, subjects, and 6 healthy young
subjects.
Exclusion criteria for all participants were chronic kidney disease
class 4 or higher, local skin disease on target skin location, presence of
tattoos on target skin location or any contra-indication against inter-
rupting the skin barrier. Clinical data regarding cardiovascular risk
profile and medical history were collected. Non-fasting glucose was
measured using a blood glucose meter with finger-stick. HbA1c and s-
creatinine/estimated glomerular filtration rate (eGFR) were retrieved
from recent (<1 month) patient records. The study was approved by the
local Medical Ethics Committee of the University Medical Center Gro-
ningen (METc 2016/258), complied with the Declaration of Helsinki and
all participants gave written informed consent.
3. Materials and methods
3.1. AGE Reader
Non-invasively assessed SAF was obtained with autofluorescence
(AGE Reader mu, DiagnOptics Technologies, NL). Excitation light, with a
peak wavelength of approximately 375 nm, is sent into the skin. SAF is
calculated by the AGE Reader as the ratio between emission light
(420–560 nm) emitted by fluorescent molecules in the skin and reflected
excitation light (300–420 nm), multiplied by 100 and expressed as
arbitrary units (AU) and corrected at low skin reflectance. Reflectance is
the calibrated reflectance at 375 nm. SAF is known to correlate with AGE
concentrations, both fluorescent and non-fluorescent, in dermal biopsies
obtained on the same site [4, 5]. SAF measurements taken over 1 single
day have been shown to have an intra-individual Altman error percent-
age of 5.03% in Caucasian subjects [4, 5].
3.2. Skin biopsies
Skin biopsies and measurements of SAF and skin pigmentation were
all performed during one visit, on a standardized location on the volar2
side of the forearm, approximately 10 cm below the elbow crease. After
subcutaneous local anesthesia with lidocaine solution (which was also
confirmed not to be fluorescent), just outside the intended biopsy area,
two 3-mm punch skin biopsies were taken and frozen in liquid nitrogen
(-196 C). Afterwards, the biopsies were transferred to a -80 C freezer.
3.3. Skin photo type assessment by the Mexameter
Skin photo type was quantified as skin pigmentation (Melanin index)
and skin redness (Erythema index), based on the concentration of he-
moglobin and melanin in the skin using the Mexameter MX 18 (CK
electronic, K€oln, GER) [18, 19]. Emitted light, in three wavelengths, is
reflected by skin and measured by a receiver. Photo type IV is determined
by a melanin content of 250–350, photo type V of 350–450 and photo
type VI of 450–999. A determination of the photo type by only measuring
the melanin is not possible due to overlapping wavelength ranges with
redness.
3.4. Immunohistochemistry, intrinsic confocal microscopy fluorescence,
UPLC-MS/MS and HPLC analysis
Several measurements were performed on transverse slices of skin
biopsies. Immunohistochemical staining was conducted with the anti-
AGE antibodies anti-CML (ab30917, Abcam, Cambridge, UK) and anti-
Nδ-(5-hydro-5-methyl-4-imidazolon-2-yl)-ornithine ([MG-H1], STA-011,
cell biolabs, inc., NL) using goat anti-mouse IgG alkaline phosphatase
(AP) conjugate ([Go-a-Mo-AP], D0486, Dako, Glostrup, DK) as chromo-
genic reporter. Histological localization of CML and MG-H1 was evalu-
ated semi-quantitatively by two independent investigators (I.M.A and
G.F.H.D). Hematoxylin and eosin (HE) stains were added to be able to
identify individual cells.
Invasively assessed intrinsic fluorescence was measured by confocal
microscopy using the ZEISS LSM 780 NLO (Zeiss, GER) and quantified by
ImageJ. We used single (405nm and 440nm) and 2-photon (750nm,
equivalent to 375nm) excitation, which corresponds to the excitation
area of the AGE Reader.
In the second skin biopsy, including epidermis and dermis, the con-
centrations of CML, MG-H1 and pentosidine were assessed by ultra-
performance liquid chromatography tandem mass spectrometry mea-
surements (UPLC-MS/MS) and high-performance liquid chromatography
(HPLC), respectively [20, 21, 22]. (Supplementary material).
3.5. Statistical analysis
Statistical analysis was limited due to the design of a pilot study,
including the small number of subjects. We combined both groups to
assess associations between SAF and skin biopsy derived data. When
reported, data are shown as median [IQR] or number. The coefficient of
variation of SAF was calculated from 3 SAF measurements. Differences in
characteristics were assessed using Mann-Whitney U tests, whereas cor-
relations were assessed using Spearman's correlations.
4. Results
4.1. Participant characteristics
The participant characteristics are shown in Table 1 and Supple-
mentary Table 1. Median age of older DM subjects was 65 [53–68] years,
of healthy young subjects 22 [20–28] years. The duration of DM was 15
[0–29] years.
SAF was 2.0 [1.6–3.1] AU in older DM subjects versus 1.4 [1.3–1.7]
AU in healthy young subjects. Analytically assessed CML, MG-H1 and
pentosidine concentrations in older DM subjects (858 nmol/mmol hy-
droxyproline [778–954]; 1648 [1245–2288]; 13 [11–16]) were higher
compared to healthy young subjects (250 nmol/mmol hydroxyproline
[203–459]; 1274 [1010–1612]; 3 [3–6]). For all excitation wavelengths
Table 1. Participant characteristics of older diabetic and healthy young subjects. Median [IQR], or n, are given.
Diabetic subjects Healthy subjects
N 6 6
Age, y 65 [53–68] 22 [20–28]
Male 5 4
Current smoker 3 1
Body Mass Index, kg/m2 23 [21–29] 23 [21–25]
Diabetes mellitus 6 0
Duration of diabetes mellitus, y 15 [0–29] N/A
HbA1c, mmol/mol 62.5 [47.8–79.0] N/A
eGFR, ml/(min/1.73m2) 67.5 [53.5–94.0] N/A
Not fasting glucose, mmol/l 8.7 [6.4–20.6] 5.9 [5.5–6.2]
Anti-hypertensive drugs 6 N/A
Lipid-lowering drugs 5 N/A
Anticoagulant therapy 4 N/A
Cardiovascular comorbidity 3 N/A
Cardiovascular comorbidity is defined as a history of stroke, cardiovascular diseases and/or use of anticoagulant therapy. HbA1c, hemoglobin A1c; eGFR, estimated
glomerular filtration rate. The eGFR was calculated using the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation [40].
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[296–453]; 440nm, 486 [366–540]; 750nm, 485 [134–563]) was higher
compared to healthy young subjects (405nm, 113 [90–147]; 440nm, 155
[143–201]; 750nm, 173 [119–259]).
The average emission from the epidermis for 2-photon 750 nm was
higher in older DM subjects compared to healthy young subjects. The
reverse applied for 405 nm and 440 nm excitation (Figure 1).
4.2. Influence of skin pigmentation
The melanin index showed higher skin pigmentation in the older DM
subjects (594.5 [431.6–722.1]) versus the healthy young subjects (320.8
[272.2–489.5]) and the UV reflectance showed a somewhat lower
reflectance (0.06 [0.05–0.07]) in the older DM subjects versus the
healthy young subjects (0.07 [0.06–0.08]). There was no correlation
between SAF and melanin index (r¼ -0.06, p¼ 0.86) or UV reflectance (r
¼ -0.12, p¼ 0.72). A negative correlation existed between UV reflectance
and the coefficient of variation of SAF (r ¼ -0.80, p < 0.01) (Figure 2).
4.3. Relationship of SAF with intrinsic fluorescence and AGE
concentrations
SAF correlated significantly with intrinsic fluorescence from the
dermis when exciting with 405 nm (r ¼ 0.58, p < 0.05) and 440 nm (r ¼
0.65, p < 0.05), but not with 750 nm (r ¼ 0.47, p ¼ 0.12). SAF did not
correlate with intrinsic fluorescence from the epidermis (405nm, r ¼
-0.37, p¼ 0.24; 440nm, r¼ -0.40, p¼ 0.20; 750nm, r ¼ -0.06, p¼ 0.85).
Furthermore, SAF showed no significant correlation with CML (r ¼ 0.54,
p ¼ 0.07), pentosidine (r ¼ 0.46, p ¼ 0.13) and MG-H1 (r ¼ -0.08, p ¼
0.81). (Figure 3).
4.4. Relationship of intrinsic fluorescence with AGE concentrations
Intrinsic fluorescence, as measured in the dermis of the skin biopsy,
correlated strongly with CML when exciting with 405 nm (r ¼ 0.90, p <
0.01) and 440 nm (r ¼ 0.75, p < 0.01), but not with 750 nm (r ¼ 0.45, p
¼ 0.15). Additionally, intrinsic fluorescence (measured in the dermis)
correlated significantly with pentosidine when exciting with 405 nm (r¼
0.79, p < 0.01). A borderline significant correlation was present when
exciting with 440 nm (r ¼ 0.57, p ¼ 0.05) and 750 nm (r ¼ 0.55, p ¼
0.06). Intrinsic fluorescence did not correlate with MG-H1. CML also
correlated significantly with pentosidine (r ¼ 0.93, p < 0.01), but not
with MG-H1 (r ¼ 0.41, p ¼ 0.19). Moreover, MG-H1 did not correlate
with pentosidine (r ¼ 0.44, p ¼ 0.15).3
4.5. Localization of AGEs by immunohistochemistry
Representative staining of AGEs in older DM subjects is shown in
Figure 4a, c, e and g, in healthy young subjects in Figure 4b, d, f and h.
CML (Figure 4a) and MG-H1 (Figure 4c) were predominantly prominent
around blood vessels, in collagen and fibroblasts in the dermis of older
DM subjects. CML (Figure 4b) showed presence in dermal fibroblasts of
healthy young subjects, and MG-H1 (Figure 4d) was located around
blood vessels and also in dermal fibroblasts. In addition, MG-H1 was
located in the epidermis in both groups. Moreover, we found positive
staining of endothelial cells in the negative controls (i.e., with omission
of the primary antibody).
Comparison between both groups demonstrated that CML was more
often present around blood vessels and in collagen in the dermis of older
DM subjects. MG-H1 staining of collagen was also more often present in
older DM subjects. Furthermore, MG-H1 staining of fibroblasts was more
often present in healthy young subjects.
Results of immunohistochemistry with anti-pentosidine were not
mentioned in the current manuscript, due to the inability to stain pen-
tosidine with the used antibody (orb27502, Biorbyt Ltd., Cambridge,
UK).
5. Discussion
To our knowledge, this proof of concept study is the first to investi-
gate advanced glycation endproducts (AGEs) in skin tissue from dark-
skinned subjects. The approach was novel compared to other studies in
dark-skinned subjects because of using both invasive and non-invasive
techniques. In previous studies concerning AGEs in skin tissue, mainly
performed in Caucasian subjects, dark-skinned subjects were underrep-
resented. This study is the first study to have taken skin biopsies in dark-
skinned subjects comparing the non-invasive SAF method with AGE
levels measured by well-established biochemical techniques and intrinsic
fluorescence. Our main finding is that SAF levels are associated with
intrinsic fluorescence in the dermis of dark-skinned subjects, but not with
CML, pentosidine and MG-H1. Our results extend previous studies
demonstrating that SAF is correlated with intrinsic fluorescence in skin
biopsies of Caucasians and Asians. Although, the correlation with indi-
vidual AGEs is limited due to a high intra-individual variance of the SAF
measurement in dark skin. Therefore, the SAF measurement is not reli-
able on an individual level in dark-skinned subjects, and attempts to
improve the non-invasive SAF measurement should be encouraged. Our
results might extend the research on SAF as a non-invasive representation
of AGEs located in dark skin.
Figure 1. Intrinsic confocal microscopy fluorescence
using excitation with 750 nm (2-photon) (a), 405 nm
(single photon) (c) and 440 nm (single photon) (e) in
representative images of skin biopsies of older dia-
betic and healthy young subjects (b, d, f). A power of
80% and a gain of 908 was used for 750 nm excita-
tion. A power of 0,2% and a gain of 755 was used for
405 nm excitation and a power of 20% and a gain of
578 was used for 440 nm excitation. Magnification:
x20. The square represents collagen. Scale bar ¼ 100
μm.
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measurement was performed at the same location as in previous studies,
allowing comparison. Less pigmentedareas, like palmsorplants,maynotbe
suitable since the epidermal layer is usually considerably thicker, and also
more variable between persons andwithin a person at different timepoints,
limiting reliable use of SAF for assessing AGE levels at these skin sites.
However, a recent study by Kim et al. [23] found that, using a novel
SAF instrument, SAF was significantly higher at palmoplantar sites in
Asian subjects with T2D complications, as compared to those without. No
differences were observed between these groups in SAF of
non-palmoplantar sites. This should open the field for further studies in
less pigmented areas.
Although our study shows novel results regarding AGEs in dark skin,
consisting of biopsy samples and non-invasive SAF measurements, the
issue of interpretation of SAF values in subjects with very dark skin (e.g.,4
Fitzpatrick V-VI) has not yet been solved [13, 24, 25]. Koetsier et al. [15]
attempted to compute reliable corrections for melanin content of skin,
using an additional white light, but this was only successful in subjects
with moderate skin pigmentation. Our findings seem to be in line with
the publications concerning measurement of SAF using another
commercialized device (SCOUT) with which measurements also are
problematic in a subset of subjects with a dark skin type [26].
Future studies should focus at sites with lower pigmentation, such as
palms or plants, or at limiting the confounding effect of other chromo-
and fluorophores in the skin which may absorb excitation light, when
assessing new SAF measurement algorithms. Moreover, the use of
polarizers is recommended. When polarizers are crossed, surface reflec-
tion will be eliminated, enhancing the measurement of autofluorescence
from the dermis [27, 28, 29]. This may further improve the SAF mea-
surement, especially in very dark-skinned subjects.
Figure 2. The association between UV reflectance and the coefficient of vari-
ation of skin autofluorescence (SAF).
Figure 3. The relationship of skin autofluorescence (SAF) with intrinsic fluo-
rescence and analytically assessed CML.
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assessed AGEs in Caucasian skin using UPLC-MS/MS and HPLC [4, 5].
Meerwaldt et al. [4, 5] reported a strong correlation between SAF and
AGEs in skin biopsies from mainly Caucasian diabetic subjects and
non-diabetic control subjects. Although the association of SAF with
CML, pentosidine, and MG-H1 was not significant, our study did show a5
significant association with intrinsic fluorescence in dark-skinned
subjects.
In addition, although it was not the objective of our study, we found
an increase of biochemically assessed AGEs in skin of older DM subjects
compared to healthy younger subjects. The amount of CML, pentosidine
and MG-H1 was higher in the older DM subjects. This is in accordance
with previous studies investigating AGE levels in Caucasians [4, 5, 17]
and Asians [7].
MG-H1 did not correlate with SAF, intrinsic fluorescence, CML and
pentosidine. MG-H1 is an AGE derived from the reaction of methyl-
glyoxal with arginine, while CML is derived from glyoxal, and pentosi-
dine from ribose, the last one occurring in the slow Maillard reaction. In
the light of these different formation pathways, it is not a surprise that
these AGEs may not be related. Also, we found a notable presence of MG-
H1 in the epidermis, which may partly explain this finding. Moreover,
previous studies in different body compartments (serum and lens pro-
teins) have shown mixed results [30, 31].
Finally, intrinsic fluorescence by confocal microscopy was more
prominent in the dermis of older DM subjects, confirming the accumu-
lation of endogenous fluorophores in dark skin, with aging and/or gly-
cemic stress. A previously conducted study by Tseng et al. [32] found that
multiphoton autofluorescence (435–700nm) intensity was increased in
glycated tissue, including skin, compared to non-glycated tissue. How-
ever, previous studies investigating the optical detection of AGEs using
confocal microscopy were so far lacking.
The current study was able to localize specific AGEs in different
components of dark skin. More particularly, CML and MG-H1 were pre-
sent around blood vessels, and colocalized with collagen and dermal fi-
broblasts. This is in accordance with earlier studies that found an
increased CML deposition in long-living tissues (e.g., collagen) [33] and
fibroblasts in skin with aging [34, 35]. In addition, a previously con-
ducted study by Murata et al. [36] showed that CML was accumulated
around vessels in human diabetic retinas.
Furthermore, CML staining was more prominent around blood vessels
and in collagen, whereas deposition of MG-H1 was more prominent in
collagen of older DM subjects, as compared to younger subjects. Our
finding is supported by a previous study by Schleicher et al. [37], stating
that CML was increased in dermal connective tissue of older DM subjects,
as compared to younger subjects. Our study is, so far, the first to report
MG-H1 deposition in the skin.
The present study has some unexpected findings. MG-H1 staining was
more often present in fibroblasts of healthy young subjects, in contrast to
older subjects with DM. This is in contrast to our expectations, based on
behavior of AGEs during aging. Since aging is associated with a decrease
in dermal blood vessels [38] and decreased collagen turnover, due to a
decrease in fibroblasts [39], this might explain the increased MG-H1
expression in fibroblasts of healthy young subjects.
In addition, for CML and pentosidine we found a strong correlation
with intrinsic fluorescence from the dermis for single photon confocal
microscopy. For 2-photon microscopy (750nm) this correlation was less
clear, which might be explained by the lower signal-to-noise in the 2-
photon images.
The present study has some limitations. First, skin color differed be-
tween our two groups, with a higher melanin index in the elderly. Blood
testing has not been conducted in the healthy younger subjects. We
assumed no abnormalities in blood parameters since our controls had no
history of diseases and had not used any medication.
Another limitation is that other studies using skin biopsies in
Caucasian subjects included more participants [4, 7, 10]. Moreover,
studies which included dark-skinned subjects were larger, but did not
conduct skin biopsies [16, 25].
Furthermore, despite the strong correlation of SAF with intrinsic
fluorescence and CML with intrinsic fluorescence, correlation of SAF
with CML showed a positive trend, but was not significant, probably
due to small data numbers, but also possibly due to unsatisfactorily
results of SAF for AGE accumulation in very dark skin types. As
Figure 4. Histology and immunostaining of skin biopsies with anti-AGE antibodies. Anti-CML (a, b), anti-MG-H1 (c, d), negative control (omission of primary
antibody) (e, f) and HE stain (g, h) in representative images of older diabetic (a, c, e and g) and healthy young subjects (b, d, f and h). Magnification: x10. The circle
represents a blood vessel, the arrow represents a fibroblast and the square represents collagen. Scale bar ¼ 100 μm.
I.M. Atzeni et al. Heliyon 6 (2020) e05364mentioned before, due to a high intra-individual variance of SAF in
dark skin, the interpretation of the SAF levels measured in this study are
hampered.
Finally, as mentioned earlier, we compared two small, explicitly
contrasting participant groups. Thus, results should be interpreted with
caution, but may be useful to calculate sample size in larger studies and
encourage further attempts to develop methods for estimating skin AGE
levels, using SAF, in dark-skinned subjects.
In conclusion, we are the first to investigate AGEs in skin tissue from
dark-skinned subjects, using both invasive and non-invasive techniques.
Although non-invasively assessed SAF and invasively measured AGEs are
associated with intrinsic fluorescence of the dermis in subjects with dark
skin on a group level, the SAF measurement is hampered in individual
patients with skin photo type V-VI due to a high intra-individual varia-
tion. Further studies to estimate skin AGE levels using SAF in dark-
skinned subjects should be encouraged since the exclusion of subjects
with skin photo type V-VI is an important limitation.6
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